CancerDrs

Brain Cancer clinical trials

300 actively recruiting brain cancer trials in the United States. Primary brain tumors including glioblastoma multiforme (GBM), lower-grade gliomas, and other CNS malignancies.

Data from ClinicalTrials.gov · last refreshed · Brain Cancer stats on SEER

77
Phase 1
101
Phase 2
11
Phase 3
2
Phase 4
109
Other

Brain Cancer by the numbers (U.S.)

24,820
Estimated new cases (2025)
18,330
Estimated deaths (2025)
33%
5-year relative survival
61
Median age at diagnosis

Source: NCI SEER Cancer Stat Facts

Browse brain cancer trials by state

Top trials by phase + site coverage

Phase 3 Recruiting Academic/Other

Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability

This phase III trial compares the effect of stereotactic radiosurgery to standard of care memantine and whole brain radiation therapy that avoids the hippocampus (the memory zone of the brain) for the treatment of small cell lung cancer th…

Sponsor: NRG Oncology
NCT ID: NCT04804644
Locations:
  • Mayo Clinic Hospital in Arizona — Phoenix, Arizona
  • Kaiser Permanente-Anaheim — Anaheim, California
  • Kaiser Permanente-Bellflower — Bellflower, California

+ 224 more sites in the U.S.

Phase 3 Recruiting NIH

A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma

This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated low-grade glioma (LGG) that does not have…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04166409
Locations:
  • Children's Hospital of Alabama — Birmingham, Alabama
  • Banner Children's at Desert — Mesa, Arizona
  • Phoenix Childrens Hospital — Phoenix, Arizona

+ 121 more sites in the U.S.

Phase 3 Recruiting Academic/Other

Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

This phase III trial compares the effect of vorasidenib to placebo in combination with usual treatment, temozolomide, in treating patients with newly diagnosed grade 3 astrocytoma after radiation. Temozolomide is in a class of medications …

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07215910
Locations:
  • City of Hope Comprehensive Cancer Center — Duarte, California
  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
  • UC Irvine Health/Chao Family Comprehensive Cancer Center — Orange, California

+ 79 more sites in the U.S.

Phase 3 Recruiting Network

Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases

Stereotactic radiosurgery (SRS) is a commonly used treatment for brain tumors. It is a one-day (or in some cases two day), out-patient procedure during which a high dose of radiation is delivered to small spots in the brain while excluding…

Sponsor: Canadian Cancer Trials Group
NCT ID: NCT03550391
Locations:
  • University of Arizona Cancer Center-Orange Grove Campus — Tucson, Arizona
  • University of Arizona Cancer Center-North Campus — Tucson, Arizona
  • City of Hope Corona — Corona, California

+ 70 more sites in the U.S.

Phase 3 Recruiting Industry

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

This is a 3-part study. The purpose of Part 1 of the study is to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of safusidenib in participants with recurrent/progressive IDH1-mutant World Health Organization (WHO) …

Sponsor: Nuvation Bio Inc.
NCT ID: NCT05303519
Locations:
  • University of Alabama — Birmingham, Alabama
  • Mayo Clinic - Arizona — Phoenix, Arizona
  • St. Joseph's Hospital and Medical Center — Phoenix, Arizona

+ 39 more sites in the U.S.

Phase 3 Recruiting Industry

Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM

The brain is protected from any toxic or inflammatory molecule by the blood-brain barrier (BBB). This physical barrier is located at the level of the blood vessel walls. Because of these barrier properties, the blood vessels are also imper…

Sponsor: CarThera
NCT ID: NCT05902169
Locations:
  • Mayo Clinic Arizona — Phoenix, Arizona
  • University of California, San Francisco — San Francisco, California
  • UCHealth — Aurora, Colorado

+ 16 more sites in the U.S.

Phase 3 Recruiting Industry

Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care

This is a Phase 3 prospective, randomized, superiority, open-label, multi-site study. The overview of this study is as follows: * A Screening/Baseline Period of 21 days. During this time, patients will be randomized into a 1:2 allocation o…

Sponsor: GT Medical Technologies, Inc.
NCT ID: NCT07195591
Locations:
  • HonorHealth Scottsdale Osborn Medical Center — Scottsdale, Arizona
  • Jersey Shore University Medical Center | Hackensack — Neptune City, New Jersey
  • Westchester Medical Center — Valhalla, New York

+ 2 more sites in the U.S.

Phase 3 Recruiting Academic/Other

Pre-Operative or Post-Operative Stereotactic Radiosurgery in Treating Patients With Operative Metastatic Brain Tumors

This phase III trial studies the side effects and how well stereotactic radiosurgery (SRS) works before or after surgery in patients with tumors that has spread to the brain or that can be removed by surgery. Stereotactic radiosurgery is a…

Sponsor: Mayo Clinic
NCT ID: NCT03750227
Locations:
  • Mayo Clinic in Arizona — Scottsdale, Arizona
  • Mayo Clinic in Florida — Jacksonville, Florida
  • National Institutes of Neurological Disorders and Stroke, NIH — Bethesda, Maryland

+ 1 more site in the U.S.

Phase 3 Recruiting Academic/Other

Pre-operative SRS or Post-operative SRS in Treating Cancer Patients With Brain Metastases

This phase III trial studies stereotactic radiosurgery (SRS) before surgery to see how well it works compared with SRS after surgery in treating patients with cancer that has spread to the brain (brain metastases). SRS is the delivery of f…

Sponsor: M.D. Anderson Cancer Center
NCT ID: NCT03741673
Locations:
  • M D Anderson Cancer Center — Houston, Texas
Phase 3 Recruiting Academic/Other

Advanced Imaging Techniques for Evaluating the Tumor Immune Microenvironment in Glioblastoma Patients

This phase III trial is evaluating whether a combination of three advanced magnetic resonance imaging (MRI) techniques, including chemical exchange saturation transfer (CEST) MRI, diffusion-relaxation correlation spectrum imaging (DR-CSI),…

Sponsor: Jonsson Comprehensive Cancer Center
NCT ID: NCT07461948
Locations:
  • UCLA / Jonsson Comprehensive Cancer Center — Los Angeles, California
Phase 3 Recruiting Academic/Other

18F-FLUC PET/MR in Patients With Brain Mets

The goal of this clinical trial is to use new imaging methods to help in finding out whether the imaging shows that there is a tumor in people with a brain metastasis. The main question it aims to answer is whether positron emission tomogr…

Sponsor: University of Wisconsin, Madison
NCT ID: NCT06159335
Locations:
  • University of Wisconsin — Madison, Wisconsin
Phase 2 Recruiting Network

A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

This phase II trial compares the effect of encorafenib, binimetinib, and nivolumab versus ipilimumab and nivolumab in treating patients with BRAF- V600 mutant melanoma that has spread to the brain (brain metastases). Encorafenib and binime…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT04511013
Locations:
  • University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
  • Thomas Hospital — Fairhope, Alabama
  • Mobile Infirmary Medical Center — Mobile, Alabama

+ 328 more sites in the U.S.

Showing 12 of 300 trials. See all on ClinicalTrials.gov

Before you contact a trial site

Trial eligibility criteria are specific and strict. Reading them carefully before calling a site saves time. These guides walk through what to look for.

Medical disclaimer: Information on this page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-07-07